BioAge Labs, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BIOA Nasdaq 2836 bioagelabs.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioAge Labs, Inc.

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates - Aug 5th, 2026 6:35 pm
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates - Aug 5th, 2026 2:50 pm
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection? - Jul 31st, 2026 3:56 pm
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 - Jul 14th, 2026 9:41 am
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction - Jul 14th, 2026 7:30 am
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation? - Jun 30th, 2026 7:09 am
BioAge Labs (BIOA) Is Up 14.2% After Starting Phase 2 Trial Of Oral NLRP3 Inhibitor - Jun 24th, 2026 6:22 pm
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk - Jun 16th, 2026 6:00 am
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease - Jun 6th, 2026 6:04 am
BioAge Labs to Present at Upcoming Investor Conferences - May 22nd, 2026 7:00 am
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage? - May 20th, 2026 2:43 pm
This CoinShares Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Wednesday - May 13th, 2026 11:43 am
AMD, Under Armour downgraded: Wall Street's top analyst calls - May 13th, 2026 7:35 am
Earnings Update: Here's Why Analysts Just Lifted Their BioAge Labs, Inc. (NASDAQ:BIOA) Price Target To US$53.33 - May 13th, 2026 6:47 am
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap, and More - May 13th, 2026 5:54 am
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials - May 8th, 2026 1:12 pm
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates - May 8th, 2026 7:00 am
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 - May 4th, 2026 2:30 pm
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile - Apr 24th, 2026 10:43 am
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year? - Apr 23rd, 2026 7:40 am